ID# 1902671 A Prospective Single Centre Study Investigating 1KHz, FAST and Microburst's Effects on PSPS Type-1
No Thumbnail Available
Authors
Poply K.
Ahmad A.
Bajaj G.
Lambe T.
Mehta, V.
Check for full-text access
Issue Date
2025
Type
Article
Language
Keywords
Alternative Title
Abstract
Introduction: Although SCS is a successful treatment for PSPS Type-1, evidence is evolving and limited by long-term data and quality of life outcomes. Additionally, there is a need to identify underlying pathology in this cohort based on imaging studies, that may contribute to failure of therapy. Based on the intricate spine anatomy inclusive of bony, ligamentous and nerve components, this evaluation can be extremely useful in predicting potential responders, particularly in the current landscape of increasing appetite for SCS use in non-surgical back pain patients. The primary objective of the study was to investigate the clinical response following neurostimulation in patients with lumbar PSPS Type-1. The secondary objective of the study was to investigate the effect on functionality, quality of life, sleep index and adverse events in the study population. The study also aimed to analyse the failure/explant rate and associated pertinent MRI factors. Method(s): Patients with intractable neuropathic pain PSPS Type-1 (n=30) were recruited (2019- 22) in a single tertiary neuromodulation centre to undergo SCS (BSC Wavewriter Alpha, dual 16 contact Infinion leads) direct to implant with anatomical placement at T9-T10. All patients underwent 1000Hz frequency stimulation until the primary end point (12 weeks) followed by real world waveforms as deemed suitable by patient and clinician compliance. NRS and data from self-report questionnaires (Oswestry Disability Index (ODI), Pain and Sleep Questionnaire (PSQ), Patient Global Impression of Change), EQ-5D-5L were collected pre-implant and at 4 weeks, 12 weeks, 6 months, 12 months and 24 months post-implant. All implanted patients underwent MRI imaging pre-operatively and images were reviewed by independent radiologist in all explants/failures to identify contributing factors. Result(s): Average NRS for back and leg improvement at 4 weeks (n=28) -49% and -54% vs. baseline; at 12 weeks (n=27) -43% and -55% vs. baseline; at 6 months (n=22) -50% and -61% vs. baseline; at 12 months (n=19), - 46% and -52% vs. baseline; at 24 month (n=13), -50% and -51% vs. baseline. ODI scores at 12 months 42.47+/-25.86 (-23% vs. baseline), and 24 months 38.55+/-23.14 (-30% vs. baseline) were reported. Detailed analysis of explants including MRI imaging will be presented at NANS. Conclusion(s): Although this long-term follow-up supports the clinical benefit of SCS up to 50% at 24 months in PSPS Type-1, there remains a need to identify patients that are poor responders in this cohort. This can potentially help in improving patient selection criteria within this group of population. Copyright © 2025
Description
Citation
Publisher
License
Journal
Neuromodulation
Volume
Issue
North American Neuromodulation Society 28th Annual Meeting.